share_log
  • Headlines
  • EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Continued Excellent Safety and Tolerability Findings, Consistent With Extensive Human Use Experience With Ondansetron'

EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Continued Excellent Safety and Tolerability Findings, Consistent With Extensive Human Use Experience With Ondansetron'

Benzinga ·  Nov 14, 2024 21:00
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Continued Excellent Safety and Tolerability Findings, Consistent With Extensive Human Use Experience With Ondansetron'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    Syros Pharmaceuticals
    SYRS
    -- 0.1817
    2seventy bio
    TSVT
    -- 4.945
    Dogwood Therapeutics
    DWTX
    -- 11.080
    Anebulo Pharmaceuticals
    ANEB
    -- 1.350
    PepGen
    PEPG
    -- 2.499
    Log In for the Full List
    Latest
    00:44
    The Carlyle Group's Chief Global Strategy Officer (CSO) and former Goldman Sachs CSI Commodity Equity Index Analyst Jeff Currie warned that the costs of metals such as Copper will incur a new "security premium". This is because tariffs mean that multiple countries need to pay more to ensure domestic supply.
    CG+1.76%
    00:43
    S&P Global Market Intelligence data shows that the Europe Crossover Default Swap Index (ITRAXX Europe Crossover Index) has widened to 308 basis points, the largest increase since January 14.
    SPGI-1.34%
    00:38
    US President Trump nominated John A. Squires, a partner at Dilworth Paxson, as the director of the US Patent and Trademark Office (USPTO) and the deputy director of intellectual property at the Department of Commerce. Previously, John A. Squires served as the head of intellectual property at Goldman Sachs.
    GS+0.02%
    Investment Course
    Choose stocks based on financial reports
    Quickly master financial season learning guidelines
    When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
    [2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
    NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
    How to view Tesla's performance in January 2025? Pay attention to these four key points.
    It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th